What is Kalion?
Kalion, Inc. operates at the intersection of synthetic biology and industrial manufacturing, specializing in the production of high-purity chemicals derived from biomass. The company's flagship focus on high-purity glucaric acid serves as a cornerstone for its diverse product portfolio, which addresses critical needs in industrial water treatment, materials science, and pharmaceutical development. By utilizing proprietary fermentation techniques, Kalion provides a sustainable and high-performance alternative to traditional chemical synthesis, effectively bridging the gap between laboratory-scale innovation and large-scale industrial deployment. Their commitment to purity and scalability positions them as a key partner for enterprises seeking to integrate bio-based materials into their supply chains.
How much funding has Kalion raised?
Kalion has raised a total of $1.7M across 2 funding rounds:
Private Equity
$697K
Private Equity
$1M
Private Equity (2015): $697K, investors not publicly disclosed
Private Equity (2017): $1M led by Cherrystone Angel Group
Key Investors in Kalion
Cherrystone Angel Group
Cherrystone Angel Group is an investment firm that focuses on providing capital to early-stage companies primarily in New England across various sectors, including life sciences, software, healthcare, and fintech.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Kalion?
With the recent influx of capital, Kalion is well-positioned to accelerate its commercialization efforts and expand its manufacturing footprint. The company's strategic roadmap likely involves scaling its fermentation infrastructure to meet the growing demand for sustainable chemical alternatives in the pharmaceutical and materials sectors. As the industry shifts toward greener manufacturing processes, Kalion's ability to deliver high-purity, bio-derived compounds provides a distinct competitive advantage. Future growth will likely focus on deepening market penetration within industrial water treatment and exploring new applications for its proprietary synthetic biology platform, ensuring long-term value creation for stakeholders and partners alike.
See full Kalion company page
